Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials.
Gastrointestinal perforation
Hepatic disorder
Rheumatoid arthritis
Upadacitinib
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
13
10
2022
revised:
30
05
2023
accepted:
03
06
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, is an effective treatment option for rheumatoid arthritis (RA), but its use has been associated with an increased risk of digestive events. This systematic review aimed to investigate the risk of digestive events in RA patients treated with UPA. Systematic searches of electronic databases (PubMed, Cochrane Library, and EMBASE) from inception to September 2022 were conducted to locate randomized controlled trials (RCTs) that compared UPA with control treatment and reported digestive events in RA patients. We pooled data using the random-effects model and meta-analysis was conducted by Stata software. Ten RCTs met the inclusion criteria and were analyzed, with a total of 6103 patients. Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), pooled analysis of 8 trials revealed no statistical difference in hepatic disorder (HD) risk and gastrointestinal (GI) perforation (GIP) risk ((OR = 1.16, 95% CI 0.86 to 1.56, I Our results showed that RA patients receiving UPA compared with csDMARDs had no significant increased risk associated with digestive events. Further long-term research of emerging data is urgently needed to gain a better understanding of the association between UPA and digestive events in the RA population.
Sections du résumé
Background
UNASSIGNED
Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, is an effective treatment option for rheumatoid arthritis (RA), but its use has been associated with an increased risk of digestive events. This systematic review aimed to investigate the risk of digestive events in RA patients treated with UPA.
Methods
UNASSIGNED
Systematic searches of electronic databases (PubMed, Cochrane Library, and EMBASE) from inception to September 2022 were conducted to locate randomized controlled trials (RCTs) that compared UPA with control treatment and reported digestive events in RA patients. We pooled data using the random-effects model and meta-analysis was conducted by Stata software.
Results
UNASSIGNED
Ten RCTs met the inclusion criteria and were analyzed, with a total of 6103 patients. Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), pooled analysis of 8 trials revealed no statistical difference in hepatic disorder (HD) risk and gastrointestinal (GI) perforation (GIP) risk ((OR = 1.16, 95% CI 0.86 to 1.56, I
Conclusion
UNASSIGNED
Our results showed that RA patients receiving UPA compared with csDMARDs had no significant increased risk associated with digestive events. Further long-term research of emerging data is urgently needed to gain a better understanding of the association between UPA and digestive events in the RA population.
Identifiants
pubmed: 37484342
doi: 10.1016/j.heliyon.2023.e17002
pii: S2405-8440(23)04209-3
pmc: PMC10361017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e17002Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Arthritis Res Ther. 2009;11(3):229
pubmed: 19519924
Lancet. 2018 Jun 23;391(10139):2513-2524
pubmed: 29908670
J Clin Rheumatol. 2022 Mar 1;28(2):e407-e414
pubmed: 33902098
Arthritis Rheumatol. 2016 Dec;68(12):2857-2866
pubmed: 27390150
Rheumatology (Oxford). 2020 Nov 1;59(11):3303-3313
pubmed: 32277824
Arthritis Rheumatol. 2019 Nov;71(11):1788-1800
pubmed: 31287230
Arthritis Res Ther. 2021 Jan 6;23(1):9
pubmed: 33407801
Mayo Clin Proc. 2020 Jul;95(7):1404-1419
pubmed: 32499126
Ann Intern Med. 1991 Nov 15;115(10):787-96
pubmed: 1834002
Bone Res. 2018 Apr 27;6:15
pubmed: 29736302
J Clin Pharmacol. 2019 Sep;59(9):1188-1194
pubmed: 30973649
Arthritis Rheumatol. 2020 Oct;72(10):1607-1620
pubmed: 32638504
Rheumatology (Oxford). 2021 May 5;60(Suppl 2):ii24-ii30
pubmed: 33950230
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
N Engl J Med. 2020 Oct 15;383(16):1511-1521
pubmed: 33053283
Arthritis Res Ther. 2019 Aug 2;21(1):183
pubmed: 31375130
Arthritis Rheum. 2011 Feb;63(2):346-51
pubmed: 20967860
Lancet. 2018 Jun 23;391(10139):2503-2512
pubmed: 29908669
Int J Rheum Dis. 2021 Dec;24(12):1530-1539
pubmed: 34779576
Ann Rheum Dis. 2014 Jul;73(7):1316-22
pubmed: 24550173
Pharmacol Res. 2022 Jan;175:106037
pubmed: 34921994
Drug Saf. 2021 Jun;44(6):711-722
pubmed: 34041702
RMD Open. 2022 Feb;8(1):
pubmed: 35121639
Arthritis Rheum. 2010 Dec;62(12):3537-46
pubmed: 20722031
Clin Rheumatol. 2022 Mar;41(3):677-688
pubmed: 34993729
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
BMJ. 1998 Feb 7;316(7129):470; author reply 470-1
pubmed: 9492687
Arthritis Rheumatol. 2016 Dec;68(12):2867-2877
pubmed: 27389975
Arthritis Rheumatol. 2016 Nov;68(11):2612-2617
pubmed: 27213279
Ann Rheum Dis. 2017 Mar;76(3):504-510
pubmed: 27405509
Expert Rev Clin Immunol. 2022 Mar;18(3):233-244
pubmed: 35129033
J Dent. 2018 Jul;74:90-94
pubmed: 29738788
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Lancet. 2019 Jun 8;393(10188):2303-2311
pubmed: 31130260
Adv Ther. 2020 May;37(5):2356-2372
pubmed: 32297280
Arthritis Care Res (Hoboken). 2012 Dec;64(12):1819-28
pubmed: 22730417
Dermatol Ther (Heidelb). 2022 Apr;12(4):835-860
pubmed: 35381976